Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors at 4 institutions in 3 countries.
Sha PengState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
Yumeng YanState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
To NgaiDepartment of Chemistry, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.ORCID 0000-0002-7207-6878
Jianjun LiState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.ORCID 0000-0002-2842-5663
Kenji OginoGraduate School of Bio-Applications and Systems Engineering, Tokyo University of Agriculture and Technology, 2-24-16 Nakacho, Tokyo 184-8588, Japan.ORCID 0000-0001-9938-6748
Yufei XiaState Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
Chinese Academy of Sciences · CNInstitute of Process Engineering · CNChinese University of Hong Kong · HKTokyo University of Agriculture and Technology · JP
Funding
Beijing Nova Program Z201100006820139CAS Project for Young Scientists in Basic Research YSBR-010Distinguished Young Scholars of the National Natural Science Foundation of China Grant No. T2222022"From 0 to 1" Original Innovation Project of Basic Frontier Scientific Research Program of Chinese Academy of Sciences ZDBS-LY-SLH040Major Project of the National Natural Science Foundation of China Grant No. 32030062the Foundation for Innovative Research Groups of the National Natural Science Foundation of China Grant No. 21821005the foundation of Innovation Academy for Green Manufacture Institute, Chinese Academy of Sciences Grand No. IAGM2020C30the National Key Research and Development Program of China 2021YFC2302605, 2021YFE020527, 2021YFC2302402the Pilot Project of Chinese Academy of Sciences Grant No. XDB29040303Youth Innovation Promotion Association of the Chinese Academy of Sciences NO. 2020000053
6 · The paper itself
Abstract
Therapeutic cancer vaccines are considered as one of the most cost-effective ways to eliminate cancer cells. Although many efforts have been invested into improving their therapeutic effect, transient maturation and activations of dendritic cells (DCs) cause weak responses and hamper the subsequent T cell responses. Here, we report on an alum-stabilized
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development and Optimal Immune Strategy of an Alum-Stabilized · full record | OpenQuestion